93221-48-8|Levobetaxolol|(S)-1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)propan-2-ol|-范德生物科技公司

Levobetaxolol

NMR下载 COA and HPLC MSDS下载
names：
(S)-1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)propan-2-ol
CAS号：
93221-48-8
MDL Number：
MF(分子式)： C18H29NO3 MW(分子量)： 307.43
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Levobetaxolol
英文别名	Levobetaxolol; (S)-Betaxolol; (S)-(-)-Betaxolol;
CAS号	93221-48-8
Inchi	InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1
InchiKey	NWIUTZDMDHAVTP-KRWDZBQOSA-N
分子式 Formula	C18H29NO3
分子量 Molecular Weight	307.43
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Levobetaxolol(CAS:93221-48-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Levobetaxolol,also known as Betaxon and AL-1577A, is a cardioselective β-adrenergic receptor inhibitor that has been demonstrated to reduce intraocular pressure in patients affected with primary open-angle glaucoma and ocular hypertension.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Quaranta L, Turano R, Pizzolante T. Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2007 Jun;1(2):93-7. PubMed PMID: 19668496; PubMed Central PMCID: PMC2704505.

[2]Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL. Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J Ocul Pharmacol Ther. 2001 Aug;17(4):305-17. PubMed PMID: 11572462.

[3] Whitson JT, Roarty JD, Vijaya L, Robin AL, Gross RD, Landry TA, Dickerson JE, Scheib SA, Scott H, Hua SY, Woodside AM, Bergamini MV; Brinzolamide Pediatric Study Group. Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial. J AAPOS. 2008 Jun;12(3):239-246.e3. doi: 10.1016/j.jaapos.2007.11.004. Epub 2008 Mar 4. PubMed PMID: 18289898.

[4] Sharif NA, Xu SX. Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol, and timolol at endogenous guinea pig beta-adrenoceptors. J Ocul Pharmacol Ther. 2004 Apr;20(2):93-9. PubMed PMID: 15117564.

[5] Agarwal N, Martin E, Krishnamoorthy RR, Landers R, Wen R, Krueger S, Kapin MA, Collier RJ. Levobetaxolol-induced Up-regulation of retinal bFGF and CNTF mRNAs and preservation of retinal function against a photic-induced retinopathy. Exp Eye Res. 2002 Apr;74(4):445-53. PubMed PMID: 12076088.

6: Osborne NN, Wood JP, Chidlow G, Casson R, DeSantis L, Schmidt KG. Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. Brain Res Bull. 2004 Feb 15;62(6):525-8. Review. PubMed PMID: 15036567.7: Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. 2016 Jan;123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005. Epub 2015 Oct 31. Review. PubMed PMID: 26526633; PubMed Central PMCID: PMC4695285.8: Sharif NA, Crider JY, Xu SX, McLaughlin M, Davis TL. Levobetaxolol (Betaxon): in vitro pharmacology, intraocular pressure lowering activity and autoradiographic localization of beta-adrenoceptors in human eyes. Proc West Pharmacol Soc. 2001;4

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开